Abstract 2430
Background
Colorectal mucosa associated lymphoid tissue (MALT) lymphoma (CML) is rare and comprises only 2.5% of the MALT lymphomas. Its etiology and treatment are not well established. The aim of this systematic literature review is trying to characterize CML and analyzing treatment failure cases treated with various therapeutic strategies.
Methods
We reviewed cases reports on colorectal lymphoma from 1993 to 2017. A PubMed search of the English medical literature was conducted using the search words "colon," "rectum," and "Maltoma" or “MALT lymphoma” as filters. Through the review, 65 case reports were found, of which 15 case reports were excluded, due to literature written in languages other than English, poorly documented cases and combined colonic disease such as adenocarcinoma or inflammatory bowel disease. After all, 67 patients reported in 50 studies were included from PubMed search. And we added 6 patients treated for CML in our multicenter institutes. Risk factor analysis was done for treatment failure, defined as remission failure and recurrence.
Results
Of 73 patients diagnosed as CML, tumors were located in rectum in 54 patients (74.0%), 10 patients (13.6%) in right colon, 3 patients (4.1%) in the transverse colon and 6 patients (8.2%) in the sigmoid colon. The patients were achieved complete response (CR) with surgery (18/19cases), local resection (18/19 cases), chemotherapy (12/13 cases), radiation therapy (4/5cases), or antibiotics therapy including Helicobacter pylori (H. pylori) eradication (12/15 cases) in the first-line treatment. Eight cases (10.9%) needed second-line treatment for remission failure, CR was achieved in 5. The tumor recurrence occurred in 5 patients in remission patients (6.8%). The multivariable analysis showed that male, multiple tumor, first-line treatment failure was significantly related with treatment failure (p = 0.03, p = 0.05, p = 0.03, respectively).
Conclusions
Complete regression of primary CML was achieved using various therapeutic strategies. The first-line treatment failure, multiple tumors were associated with treatment failure, although the numbers of failure cases are too small to draw definitive conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract